Houston-based TRISH's research will be done aboard the Polaris Dawn by its crew, which includes, from left to right, Mission Specialist and Medical Officer Anna Menon, Mission Pilot Scott “Kidd” Poteet, Mission Commander Jared “Rook” Isaacman, Mission Specialist Sarah Gillis. Photo courtesy Polaris Program/John Kraus

The Translational Research Institute for Space Health at Baylor College of Medicine, or TRISH, announced this month that it will perform research experiments aboard SpaceX's upcoming Polaris Dawn mission that will look into everything from human vision to motion sickness to radiation levels while in space.

The research aboard Polaris Dawn will complement research supported by TRISH on the Inspiration4 all-civilian mission to orbit, which was also operated by SpaceX in 2021.

“The Institute’s mission is to help humans thrive in deep space,” Dr. Dorit Donoviel, TRISH executive director and associate professor for the Center for Space Medicine at Baylor, said in a statement. “We are grateful to our commercial space exploration partners, and in particular, the Polaris Program, who recognize how important it is to carry out and support health research in their missions, as a route to improving health for all humans in space and on Earth.”

Polaris Dawn is slated to launch from NASA’s Kennedy Space Center in Florida no earlier than March 2023. It is part of SpaceX's Polaris Program, which proposes three space missions. The first mission aims to reach the highest Earth orbit ever flown.

Four crew members will be onboard SpaceX’s Falcon 9 rocket for the Polaris Dawn mission. TRISH's experiments are part of 38 experiments from institutions that will be conducted on board at high-altitude Earth orbit.

The experiments are supported by federal funding from TRISH's cooperative agreement with NASA, as well as a donation from the Polaris Program.

According to a statement from TRISH, the experiments will include the following:

  • Collecting data related to the vision condition Spaceflight Associated Neuro-Ocular Syndrome (SANS), which is a top risk to human health in long-duration spaceflight
  • Quantifying alterations in body composition and fluid distribution during exposure to weightlessness
  • Directly measuring intracranial pressure changes to quantify the effects of weightlessness on the brain
  • Measuring cognitive performance, which reflects fitness for duty
  • Collecting biometric data to track physiologic changes, which could inform on changes in overall health
  • Using miniaturized, intelligent ultrasound to train the astronauts to scan themselves and deliver medical quality images
  • Testing ways to predict space motion sickness to improve crew safety and in-mission performance
  • Collecting data on the radiation environment to observe how space radiation may affect human systems
  • Providing biological samples for multi-omics analyses and storage in a long-term biobank to be available to researchers in the future

TRISH launched the first-ever commercial spaceflight medical research program in 2021, known as the Expand—Enhancing Exploration Platforms and Analog Definition—Program. Future findings from the Polaris Dawn mission will be added to the database, which compiles in-flight health data from multiple spaceflights.

TRISH was founded in 2016 with the mission of addressing the most pressing health risks and challenges associated with human deep space exploration.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston femtech co. debuts new lactation and wellness pods

mom pod

Houston-based femtech company Work&, previously known as Work&Mother, has introduced new products in recent months aimed at supporting working mothers and the overall health of all employees.

The company's new Lactation Pod and Hybrid Pod serve as dual-use lactation and wellness spaces to meet employer demand, the company shared in a news release. The compact pods offer flexible design options that can serve permanent offices and nearly all commercial spaces.

They feature a fully compliant lactation station while also offering wellness functionalities that can support meditation, mental health, telehealth and prayer. In line with Work&'s other spaces, the pods utilize the Work& scheduling platform, which prioritizes lactation bookings to help employers comply with the PUMP Act.

“This isn’t about perks,” Jules Lairson, Work& co-founder and COO, said in the release. “It’s about meeting people where they are—with dignity and intentional design. That includes the mother returning to work, the employee managing anxiety, and everyone in between.”

According to the company, several Fortune 500 companies are already using the pods, and Work& has plans to grow the products' reach.

Earlier this year, Work& introduced its first employee wellness space at MetroNational’s Memorial City Plazas, representing Work&'s shift to offer an array of holistic health and wellness solutions for landlords and tenants.

The company, founded in 2017 by Lairson and CEO Abbey Donnell, was initially focused on outfitting commercial buildings with lactation accommodations for working parents. While Work& still offers these services through its Work&Mother branch, the addition of its Work&Wellbeing arm allowed the company to also address the broader wellness needs of all employees.

The company rebranded as Work& earlier this year.

Rice biotech studio secures investment from Modi Ventures, adds founder to board

fresh funding

RBL LLC, which supports commercialization for ventures formed at the Rice University Biotech Launch Pad, has secured an investment from Houston-based Modi Ventures.

Additionally, RBL announced that it has named Sahir Ali, founder and general partner of Modi Ventures, to its board of directors.

Modi Ventures invests in biotech companies that are working to advance diagnostics, engineered therapeutics and AI-driven drug discovery. The firm has $134 million under management after closing an oversubscribed round this summer.

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. William McKeon, president and CEO of the TMC, previously called the launch of RBL a “critical step forward” for Houston’s life sciences ecosystem.

“RBL is dedicated to building companies focused on pioneering and intelligent bioelectronic therapeutics,” Ali said in a LinkedIn post. “This partnership strengthens the Houston biotech ecosystem and accelerates the transition of groundbreaking lab discoveries into impactful therapies.”

Ali will join board members like managing partner Paul Wotton, Rice bioengineering professor Omid Veiseh, scientist and partner at KdT Ventures Rima Chakrabarti, Rice alum John Jaggers, CEO of Arbor Biotechnologies Devyn Smith, and veteran executive in the life sciences sector James Watson.

Ali has led transformative work and built companies across AI, cloud computing and precision medicine. Ali also serves on the board of directors of the Drug Information Association, which helps to collaborate in drug, device and diagnostics developments.

“This investment by Modi Ventures will be instrumental to RBL’s growth as it reinforces confidence in our venture creation model and accelerates our ability to develop successful biotech startups,” Wotton said in the announcement. "Sahir’s addition to the board will also amplify this collaboration with Modi. His strategic counsel and deep understanding of field-defining technologies will be invaluable as we continue to grow and deliver on our mission.”